Visionweb & Neurolens Collaborate to Increase Prism Specificity

Through VisionWeb's ordering platform, prism can now be entered to the 1/100th prism diopter

Ongoing research from a myriad of sources has indicated that at least two out of three patients experience the symptoms of eye misalignment, and the rapid acceleration in remote working and learning over the past two years has undoubtedly led to a rise in this figure. Optical prisms are one of the most commonly employed treatment modalities to correct these binocular vision issues.

As such, technological innovations in this space will become increasingly important to the future of eyecare. In order to ensure that eyecare providers are able to meet these growing challenges, Neurolens and VisionWeb have worked together to expand the prism field from 1/4th prism diopter to 1/100th prism diopter when placing orders through VisionWeb’s ordering platform.

“At Neurolens, we strongly believe that the eyecare industry must evolve beyond visual acuity to own the visual comfort space as well,” says Pierre Bertrand, Chief Executive Officer of Neurolens. “A large and growing percentage of the population is suffering from the symptoms of binocular vision issues—some on a daily basis—and Neurolenses provide proven relief for these patients. We are proud to collaborate with an industry leader like VisionWeb to ensure that eyecare providers can prescribe optical prism to the specificity required to meet the needs of today’s patients.”

This expanded prism range will allow Neurolens providers to take advantage of the highly accurate measurements from the Neurolens Measurement Device (NMD) and Neurolens Measurement Device, Gen 2 (NMD2) and prescribe precise prism measurements for their patients. “We are learning more every day about how small amounts of prism can create tremendous symptom relief for patients,” says Vivek Labhishetty BSc Optometry, MSc, PhD, Director of Clinical Research for Neurolens. “This creates an imperative to ensure prism measurements can be entered with a high degree of specificity to maximize the number of patients that can be helped by this technology.”

Mike Bonacci, Director of Integrations at VisionWeb says, “We are on a mission to make it easier for people in the eyecare industry to do their jobs, and we will continue to pioneer technology that enables eyecare providers to more efficiently conduct business and meet the needs of their patients. This development sends yet another signal that VisionWeb will make every effort to remain on the forefront of emerging trends in practice management and patient care.”

SourceNeurolens

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”